Introduction {#S1}
============

DNA methylation plays an essential role in the epigenetic control of gene expression in cancer ([@R1]--[@R3]). The DNA methyltransferases (DNMTs) are responsible for methylation of DNA through transfer of a methyl group to the cytosine base in CpG dinucleotides ([@R1]). DNMT1 localizes to replication foci and is primarily responsible for maintaining DNA methylation patterns from template strands to newly synthesized DNA strands ([@R4]). DNMT1 can function with DNMT3a and DNMT3b in de novo methyltransferase activity during development ([@R5]; [@R6]). Moreover, DNMT3a and DNMT3b establish de novo postreplicative DNA methylation patterns ([@R7]; [@R8]). DNMT1, DNMT3a and DNMT3b are often overexpressed in cancer cells ([@R9]--[@R11]). Transcriptional activation of the *DNMT1, DNMT3a* and *DNMT3b* genes has been linked to activation of the RAS-JUN pathway ([@R12]; [@R13]) and to binding of the Sp1 and Sp3 zinc finger proteins to their promoters ([@R14]; [@R15]). In addition, DNMT1, DNMT3a and DNMT3b expression is repressed by (i) p53, Rb and FOXO3a, and (ii) diverse miRNAs ([@R16]). Notably, DNMT1 and DNMT3b are both needed to silence genes in human cancer cells ([@R17]; [@R18]). However, signaling pathways that selectively and coordinately induce DNMT1 and DNMT3b are not known.

Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly overexpressed by breast, lung and diverse other carcinomas ([@R19]; [@R20]). The oncogenic MUC1 C-terminal transmembrane subunit (MUC1-C) associates with receptor tyrosine kinases at the cell membrane and promotes their downstream signaling pathways ([@R19]; [@R20]). MUC1-C also localizes to the nucleus, where it interacts with certain transcription factors and contributes to their transactivation function ([@R19]; [@R20]). In this manner, MUC1-C has been linked to the NF-κB pathway through interactions with TAK1 ([@R21]) and the IKK complex ([@R22]). MUC1-C also binds directly to NF-κB p65 and thereby contributes to activation of NF-κB target genes, including *MUC1* itself, in an autoinductive loop ([@R23]). Involvement of MUC1-C in the TAK1→IKK→NF-κB p65 pathway in cancer cells has further supported a direct role for MUC1-C in induction of (i) inflammatory cytokines, including IL-8, (ii) the epithelial-mesenchymal transition (EMT) with downregulation of the *CDH1* gene that encodes E-cadherin (ECAD) and (iii) self-renewal capacity ([@R21]--[@R25]). These findings have supported the notion that MUC1-C contributes to cancer progression by multiple mechanisms.

Based on the premise that MUC1-C is of importance to the regulation of gene expression in cancer, the present studies investigated whether MUC1-C induces DNMT expression and alterations in DNA methylation patterns. The results demonstrate that MUC1-C selectively and coordinately activates the *DNMT1* and *DNMT3b* genes in cancer cells and thereby global and gene-specific changes in DNA methylation.

Results and Discussion {#S2}
======================

Stable silencing of MUC1-C in BT-549 breast cancer cells was associated with suppression of DNMT1 mRNA and protein ([Fig. 1A](#F1){ref-type="fig"}). A similar response to MUC1-C silencing was observed in MDA-MB-231 breast cancer cells ([Fig. 1B](#F1){ref-type="fig"}), indicating that MUC1-C promotes DNMT1 expression. To confirm this notion, we overexpressed MUC1-C in MCF-7 breast cancer cells ([@R24]) and observed an increase in DNMT1 mRNA and protein ([Fig. 1C](#F1){ref-type="fig"}), indicating that MUC1-C, and not the MUC1 N-terminal subunit (MUC1-N), is sufficient for this response. In extending these observations to other types of carcinomas, we found that silencing MUC1-C in KRAS mutant A549 ([Fig. S1A](#SD1){ref-type="supplementary-material"}) and H460 ([Fig. S1B](#SD1){ref-type="supplementary-material"}) non-small cell lung cancer (NSCLC) cells similarly results in decreased DNMT1 expression. In addition, MUC1-C conferred DNMT1 expression in SK-CO-1 colon cancer cells ([Fig. S1C](#SD1){ref-type="supplementary-material"}), indicating that this association is found in diverse types of carcinomas. In further studies, we found that silencing MUC1-C in BT-549 cells suppressed DNMT3b, but not DNMT3a, expression ([Fig. 1D](#F1){ref-type="fig"}). The same pattern of response was observed in MDA-MB-231 ([Fig. 1E](#F1){ref-type="fig"}), A549 NSCLC ([Fig. S2A](#SD2){ref-type="supplementary-material"}), H460 NSCLC cells ([Fig. S2B](#SD2){ref-type="supplementary-material"}), and SK-CO-1 colon cancer cells ([Fig. S2C](#SD2){ref-type="supplementary-material"}). We also found that overexpression of MUC1-C in MCF-7 cells increases DNMT3b and not DNMT3a ([Fig. 1F](#F1){ref-type="fig"}). To provide additional support for these findings, we used other approaches for targeting MUC1-C expression. In this way, silencing MUC1 in H460 cells with clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 editing resulted in the downregulation of DNMT1 and DNMT3b ([Fig. S3A](#SD3){ref-type="supplementary-material"}). Moreover, targeting MUC1-C function in BT-549 and A549 cells with the GO-203 inhibitor ([@R26]) decreased DNMT1 and DNMT3b levels ([Figs. S3B and S3C](#SD3){ref-type="supplementary-material"}). These results demonstrate that MUC1-C selectively drives DNMT1 and DNMT3b, but not DNMT3a, expression in breast and other carcinoma cells.

Based on these findings, we searched the *DNMT1* and *DNMT3b* promoters for the presence of cis-binding elements not shared with *DNMT3a*. Notably, an NF-κB binding site had been reported in the *DNMT1* promoter ([Fig. 2A](#F2){ref-type="fig"}) ([@R27]) and putative consensus NF-κB sites were identified in the *DNMT3b*, but not in the *DNMT3a,* promoter ([Fig. 2B](#F2){ref-type="fig"}). Accordingly and to investigate a transcriptional mechanism, we generated a DNMT1 promoter-luciferase reporter (pDNMT1-Luc) ([Fig. S4A](#SD4){ref-type="supplementary-material"}) and showed that silencing MUC1-C in MDA-MB-231 ([Fig. 2A](#F2){ref-type="fig"}, left) and A549 ([Fig. S4B](#SD4){ref-type="supplementary-material"}) cells suppresses its activity. A similar experiment using a DNMT3b promoter-luciferase reporter (pDNMT3b-Luc) ([Fig. S4C](#SD4){ref-type="supplementary-material"}) demonstrated that silencing MUC1-C is also associated with decreased activation ([Fig. 2B](#F2){ref-type="fig"}, left and [Fig. S4D](#SD4){ref-type="supplementary-material"}). In addition, mutation of the putative NF-κB p65 binding sites in the pDNMT1-Luc ([Fig. 2A](#F2){ref-type="fig"}, right) and pDNMT3b-Luc ([Fig. 2B](#F2){ref-type="fig"}, right) vectors decreased their activation. To extend this line of investigation, we found that silencing NF-κB p65 in BT-549 and MDA-MB-231 cells decreases DNMT1 and DNMT3b, but not DNMT3a, expression ([Figs. 2C and 2D](#F2){ref-type="fig"}). Similar results were obtained in A549 cells ([Fig. S4E](#SD4){ref-type="supplementary-material"}). Moreover, treatment with the NF-κB inhibitor BAY11-7085 ([@R28]) decreased expression of DNMT1 and DNMT3b, and not DNMT3a ([Fig. 2E](#F2){ref-type="fig"}). MUC1-C constitutively activates the NF-κB p65 pathway in mesenchymal MDA-MB-231 and BT-549, but not in luminal MCF-7, cells. However, the enforced overexpression of MUC1-C in MCF-7 cells induces NF-κB p65 activity ([@R25]), indicating that cell context is of importance for MUC1-C-induced activation of NF-κB p65 signaling. Indeed, in studies of MCF-7/MUC1-C cells, we also found that BAY11-7085 (i) attenuates activation of the DNMT1 promoter ([Fig. 2F](#F2){ref-type="fig"}, left), and (ii) suppresses DNMT1 and DNMT3b expression ([Fig. 2F](#F2){ref-type="fig"}, right), providing further evidence that the MUC1-C→NF-κB p65 pathway ([@R21]--[@R23]) confers *DNMT1* and *DNMT3b* activation.

MUC1-C binds directly to NF-κB p65 and promotes activation of NF-κB target genes, including *MUC1* itself in an autoinductive loop ([@R23]). To investigate whether MUC1-C occupies the *DNMT1* and *DNMT3b* promoters, we performed chromatin immunoprecipitation (ChIP) studies on MDA-MB-231 cells. Analysis of the *DNMT1* promoter clearly demonstrated MUC1-C occupancy ([Fig. 3A](#F3){ref-type="fig"}, left) and the presence of NF-κB p65 ([Fig. 3A](#F3){ref-type="fig"}, right). Additionally, in re-ChIP experiments, we found that NF-κB p65 occupies the *DNMT1* promoter in a complex with MUC1-C ([Fig. 3B](#F3){ref-type="fig"}), consistent with the above observation that *DNMT1* activation is dependent on both MUC1-C and NF-κB p65. We also found that silencing MUC1-C decreases occupancy of NF-κB p65 on the *DNMT1* promoter ([Fig. 3C](#F3){ref-type="fig"}). Similar results were obtained from studies of the *DNMT3b* promoter; that is MUC1-C and NF-κB p65 occupancy ([Fig. 3D](#F3){ref-type="fig"}, left and right) and the detection of MUC1-C/NF-κB p65 complexes ([Fig. 3E](#F3){ref-type="fig"}). The results also demonstrate that MUC1-C promotes NF-κB p65 occupancy of the *DNMT3b* promoter ([Fig. 3F](#F3){ref-type="fig"}).

The above findings invoked the possibility that MUC1-C also functions in regulating DNA methylation in cancer cells. Indeed, silencing MUC1-C in BT-549 ([Fig. 4A](#F4){ref-type="fig"}) and MDA-MB-231 ([Fig. S5A](#SD5){ref-type="supplementary-material"}) cells was associated with significant decreases in the percentage of 5-mC in Long Interspersed Nucleotide Element-1 (LINE-1) repeats, a surrogate marker of global DNA methylation ([@R29]--[@R31]). These effects of targeting MUC1-C were confirmed using bisulfite sequencing of LINE-1 repeats ([Fig. 4B](#F4){ref-type="fig"}), further supporting a role for MUC1-C in inducing global DNA methylation. Based on these results and previous work demonstrating that MUC1-C promotes EMT and downregulation of ECAD expression ([@R24]; [@R25]), we investigated the involvement of MUC1-C in DNA methylation of the *CDH1* promoter. Using immunoprecipitation of methylated DNA (MeDIP) followed by qPCR of the precipitated DNA fragments, we found that silencing MUC1-C in MDA-MB-231 cells is associated with marked decreases in methylation of the *CDH1* promoter ([Fig. S5B](#SD5){ref-type="supplementary-material"}). In addition and in concert with this response, MUC1-C silencing resulted in significant induction of ECAD mRNA and protein ([Fig. S5C](#SD5){ref-type="supplementary-material"}). Similarly, silencing MUC1-C in BT-549 cells was associated with decreased methylation of the *CDH1* promoter and induction of ECAD expression ([Fig. 4C](#F4){ref-type="fig"}). Additionally, bisulfite conversion of genomic DNA and pyrosequencing of the CpG region of the *CDH1* promoter (positions −169 to −116) demonstrated that MUC1-C silencing is associated with significant decreases in DNA methylation of multiple CpG sites ([Fig. 4D](#F4){ref-type="fig"}).

Aberrant expression of DNMTs and changes in DNA methylation have been linked to cancer cell progression and survival ([@R2]; [@R9]; [@R11]; [@R32]; [@R33]). Interestingly, genetic disruption of both *DNMT1* and *DNMT3b* substantially reduces DNMT activity and DNA methylation, indicating that these DNMTs cooperate to silence genes in human cancer cells ([@R18]). The present findings demonstrate that the MUC1-C oncoprotein is unique in that it selectively and coordinately induces DNMT1 and DNMT3b, but not DNMT3a, expression and thereby upregulates DNA methylation in diverse types of carcinoma cells ([Fig. 4E](#F4){ref-type="fig"}). MUC1-C activates the TAK1→IKK→NF-κB pathway in an autoinductive loop that includes a direct interaction with NF-κB p65 and the induction of *MUC1* and other NF-κB target genes ([@R19]--[@R23])([Fig. 4E](#F4){ref-type="fig"}). The present results thus provide support for a model in which MUC1-C→NF-κB p65 signaling links this inflammatory response to the induction of DNMTs ([Fig. 4E](#F4){ref-type="fig"}). Based on these findings, we investigated the effects of targeting MUC1-C on DNA methylation patterns. LINE-1 retrotransposons constitute approximately 17--18% of the human genome, are aberrantly activated in cancer and may contribute to genome instability ([@R34]; [@R35]). Based on the demonstration that MUC1-C regulates LINE-1 DNA methylation, experiments will be needed to assess whether MUC1-C has an effect on LINE-1 retrotransposon activity in cancer cells. In this regard and although global hypomethylation promotes LINE-1 activation in cancer cells, individual LINE-1 elements are activated only when hypomethylation occurs in the promoter region of that element ([@R36]; [@R37]).

MUC1-C has been linked to induction of EMT and the associated downregulation of ECAD expression in cancer cells ([@R24]; [@R25]). The present results extend the importance of MUC1-C in EMT by demonstrating that MUC1-C drives DNA methylation of the *CDH1* promoter and thereby suppression of ECAD expression. These findings do not exclude the possibility that MUC1-C suppresses ECAD expression by additional mechanisms; for example, by promoting SNAIL-mediated repression of the *CDH1* promoter ([@R38]). The finding that targeting MUC1-C reverses EMT also raises the possibility that MUC1-C may epigenetically regulate other genes in the EMT program ([@R24]; [@R25]). In that line of reasoning, the *MUC1* promoter itself is regulated by DNA methylation ([@R39]--[@R41]). Accordingly, studies of interest will be to assess the effects of downregulating DNMT1 and/or DNMT3b on DNA methylation of the *MUC1* promoter and MUC1-C expression. In summary, the present findings support the premise that targeting MUC1-C could represent a therapeutic approach capable of influencing global and gene-specific epigenetic changes, and in turn the reprogramming of cancer cells.
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![MUC1-C induces DNMT1 and DNMT3b, but not DNMT3a, in human carcinoma cells\
(A--B) BT-549 (A) and MDA-MB-231 (B) breast cancer cells stably expressing a Control shRNA (CshRNA) or a MUC1 shRNA (MUC1shRNA) were analyzed for MUC1 and DNMT1 mRNA levels by qRT-PCR with pairs of primers listed in [Table S1](#SD6){ref-type="supplementary-material"}. The results (mean±SD of 3 determinations) are expressed as relative mRNA levels compared to that obtained with cells expressing MUC1shRNA (assigned a value of 1) (left and middle panels). Lysates were immunoblotted with the indicated antibodies (right panels). (C) MCF-7 breast cancer cells stably expressing an empty vector (MCF-7/vector) or MUC1-C (MCF-7/MUC1-C) were analyzed for DNMT1 mRNA levels by qRT-PCR. The results (mean±SD of 3 determinations) are expressed as relative mRNA levels compared to that obtained for vector expressing cells (assigned a value of 1) (left panel). Lysates from the indicated cells were analyzed by immunoblotting (right panel). (D--E) The indicated BT-549 (D) and MDA-MB-231 (E) cells were analyzed for (i) DNMT3a (left panels) and DNMT3b mRNA (middle panels). The results (mean±SD of 3 determinations) are expressed as relative mRNA levels compared to that obtained with cells expressing MUC1shRNA (assigned a value of 1). Lysates were analyzed by immunoblotting with the indicated antibodies (right panels). (F) MCF-7/vector and MCF-7/MUC1-C cells were analyzed for DNMT3a (left panel) and DNMT3b (middle panel) mRNA levels by qRT-PCR (mean±SD of 3 determinations) as compared to that obtained for vector expressing cells (assigned a value of 1). Lysates from the indicated cells were analyzed by immunoblotting (right panel).](nihms777809f1){#F1}

![MUC1-C activates DNMT1 and DNMT3b expression by an NF-κB-mediated mechanism\
(A) Schema of the DNMT1 promoter-luciferase (pDNMT1-Luc) reporter with an NF-κB binding motif at -833 to -824 upstream to the transcription start site. MDA-MB-231 cells were transfected with (i) the empty pGL3-Basic Luc vector or pGL3-pDNMT1-Luc, and the SV-40-*Renilla*-Luc plasmid as an internal control (left), and the empty pGL3-Basic Luc vector, wild-type (WT) pGL3-pDNMT1-Luc or mutant pGL3-pDNMT1-Luc and the SV-40-*Renilla*-Luc plasmid (right). Dual luciferase activity was measured at 48 h after transfection. The results (mean±SD of 3 determinations) are expressed as the relative luciferase activity compared to that obtained with (i) the MDA-MB-231/MUC1shRNA cells (assigned a value of 1)(left) and (ii) the mutant pGL3-pDNMT1-Luc (assigned a value of 1) (right). (B) Schema of the DNMT3b promoter-Luciferase (pDNMT3b-Luc) reporter with two putative consensus NF-κB binding sites at the indicated positions. MDA-MB-231 cells were transfected with the pGL3 vector, wild-type (WT) pGL3-pDNMT3b-Luc or mutant pGL3-pDNMT3b-Luc and SV-40-*Renilla*-Luc. The cells were then analyzed for luciferase activity as described above. (C--D) Lysates from the BT-549 (C) and MDA-MB-231 (D) cells without and with p65 silencing were immunoblotted with the indicated antibodies. (E) Lysates from BT-549 cells treated with control vehicle (DMSO) or 10 μM BAY11-7085 for 24 h were immunoblotted with the indicated antibodies. (F) MCF-7/MUC1-C cells were transfected with the pGL3 or pGL3-pDNMT1-Luc, and the SV-40-*Renilla*-Luc plasmid. The cells were also treated with control vehicle (DMSO) or 10 μM BAY11-7085. Luciferase activity was measured at 48 h after transfection. The results (mean±SD of 3 determinations) are expressed as the relative luciferase activity compared to that obtained with BAY11-7085-treated cells (assigned a value of 1). MCF-7/MUC1-C cells were treated with control vehicle (DMSO) or 10 μM BAY11-7085 for 24 h. Lysates were immunoblotted with the indicated antibodies (right).](nihms777809f2){#F2}

![MUC1-C occupies the *DNMT1* and *DNMT3b* promoters\
(A--F) (A and D) Soluble chromatin from MDA-MB-231 cells was precipitated with anti-MUC1-C (left), anti-p65 (right) or a control IgG. (B and E) In re-ChIP studies, the anti-p65 precipitates were released and reimmunoprecipitated with IgG or anti-MUC1-C. (C and F) Soluble chromatin from MDA-MB-231/CshRNA and MDA-MB-231/MUC1shRNA cells was precipitated with anti-p65 or a control IgG. (A--C) The final DNA samples were amplified by qPCR with pairs of primers ([Table S2](#SD7){ref-type="supplementary-material"}) for the NF-κB p65 binding site in the DNMT1 promoter. The results (mean±SD of 3 determinations) are expressed as the relative fold enrichment compared with that obtained for the IgG control (assigned a value of 1). (D--F) The final DNA samples were amplified by qPCR with pairs of primers ([Table S2](#SD7){ref-type="supplementary-material"}) for the NF-κB p65 binding sites in the *DNMT3b* promoter. The results (mean±SD of 3 determinations) are expressed as the relative fold enrichment compared with that obtained for the IgG control (assigned a value of 1).](nihms777809f3){#F3}

![MUC1-C induces LINE-1 and *CDH1* promoter DNA methylation\
(A) Genomic DNA from the indicated BT-549 cells was analyzed using the LINE-1 global DNA methylation ELISA kit. The results are expressed as percentage 5-mC (mean±SD of 3 determinations) based on extrapolation from the methylated and unmethylated genomic standards provided in the kit. (B) Genomic DNA from BT-549/CshRNA (closed bars) and BT-549/MUC1shRNA (open bars) was analyzed by bisulfite conversion, PCR amplification and pyrosequencing of 4 CpG positions in the LINE-1 element. The results are expressed as the percentage DNA methylation (mean±SD of 3 determinations) at each of the 4 positions as compared to that obtained in BT-549/CshRNA cells (assigned a value of 100%). The asterisk (\*) denotes a p value of \<0.05. (C) Genomic DNA from BT-549 cells was subjected to immunoprecipitation of methylated DNA (MeDIP) and the precipitates were analyzed by qPCR of the *CDH1* promoter (positions −213 to −116). The results (mean±SD of 3 determinations) are expressed as relative fold enrichment compared to that obtained from MUC1shRNA expressing cells (assigned a value of 1)(left panel). Lysates from the indicated cells were analyzed by immunoblotting (right panel). (D) Genomic DNA from BT-549/CshRNA (closed bars) and BT-549/MUC1shRNA (open bars) was analyzed by bisulfite conversion, PCR amplification and pyrosequencing of the indicated CpG sites in the *CDH1* promoter. The results are expressed as the percentage DNA methylation (mean±SD of 3 determinations) at each of the 6 CpG sites. The hashtag (\#) and asterisk (\*) denote p values of \>0.05 and \<0.05, respectively. (E) Schema depicting the proposed MUC1-C-induced expression of DNMT1 and DNMT3b, and thereby DNA methylation in human cancer cells. MUC1-C induces an autoinductive inflammatory circuit involving activation of the TAK1→IKK→NF-κB p65 pathway ([@R21]--[@R23]). MUC1-C promotes NF-κB p65-mediated induction of *DNMT1* and *DNMT3b* transcription by interacting with NF-κB p65 on their respective promoters and increasing NF-κB p65 occupancy. In turn, MUC1-C links the inflammatory response with induction of DNA methylation and regulation of gene expression. Thus, targeting MUC1-C in cancer cells with silencing or inhibitors suppresses (i) DNMT1 and DNMT3b expression, and (ii) global and promoter-specific DNA methylation.](nihms777809f4){#F4}
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